Cargando…

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age

INTRODUCTION: Breast cancer in young women (<50 years) has been associated with an increased risk of recurrence and decreased survival compared with patients older than 50. The objective of this analysis was to determine, from a large database of patients with early-stage breast cancer, if the Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swain, Sandra M., Nunes, Raquel, Yoshizawa, Carl, Rothney, Megan, Sing, Amy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679789/ https://www.ncbi.nlm.nih.gov/pubmed/26610382 http://dx.doi.org/10.1007/s12325-015-0268-3

Ejemplares similares

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
por: Alvarado, Michael D., et al.
Publicado: (2015)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer
por: Frazier, Thomas G., et al.
Publicado: (2015)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
por: Cohen, Pascale A., et al.
Publicado: (2019)

High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer
por: Chervoneva, Inna, et al.
Publicado: (2023)

MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer
por: Schulze, Amy, et al.
Publicado: (2020)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy
por: Stemmer, Salomon M., et al.
Publicado: (2019)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
por: Ahn, Sung Gwe, et al.
Publicado: (2017)

RCC2 Expression Stimulates ER-Positive Breast Tumorigenesis
por: Wang, Weiqi, et al.
Publicado: (2020)

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
por: Yu, Jing, et al.
Publicado: (2021)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
por: Ahlin, Cecilia, et al.
Publicado: (2017)

Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis
por: Stabellini, Nickolas, et al.
Publicado: (2023)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
por: Zhou, Xin, et al.
Publicado: (2014)

The Quantitative ER Immunohistochemical Analysis in Breast Cancer: Detecting the 3 + 0, 4 + 0, and 5 + 0 Allred Score Cases
por: Ilić, Ivan R., et al.
Publicado: (2019)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013
por: Parsons, Benjamin M., et al.
Publicado: (2016)

Elastosis in ERα-positive male breast cancer
por: Vermeulen, Marijn A., et al.
Publicado: (2020)

Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer
por: Zheng, Zao-zao, et al.
Publicado: (2022)

High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer
por: Onaga, Chotaro, et al.
Publicado: (2022)

Apoptosis/Necrosis Induction by Ultraviolet, in ER Positive and ER Negative Breast Cancer Cell Lines
por: Shokrollahi Barough, Mahdieh, et al.
Publicado: (2015)

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
por: Zhang, Wen-Wen, et al.
Publicado: (2019)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
por: Pestalozzi, Bernhard C., et al.
Publicado: (2017)

Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy
por: Kim, Tae-Jung, et al.
Publicado: (2012)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2020)

A consensus prognostic gene expression classifier for ER positive breast cancer
por: Teschendorff, Andrew E, et al.
Publicado: (2006)

Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor–positive, Node-positive Breast Cancer
por: Brufsky, Adam M.
Publicado: (2014)

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells
por: Deng, Hao, et al.
Publicado: (2014)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
por: Emmadi, Rajyasree, et al.
Publicado: (2015)

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
por: Stemmer, Salomon M., et al.
Publicado: (2017)

The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
por: Gao, Yang, et al.
Publicado: (2015)

The prognostic effects of somatic mutations in ER-positive breast cancer
por: Griffith, Obi L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c3arikd4pu8olnso7rn3uu0a44